Diagnosed with Lymphoma during COVID — how has treatment changed

How Lymphoma Treatment Has Evolved Since COVID

That's a great question, and it's understandable to wonder how much has changed since your diagnosis. The field of lymphoma treatment has made some meaningful advances in recent years, though the core approaches remain similar. Let me walk you through what's new.

Key Treatment Advances Since COVID

1. CAR T-Cell Therapy Expansion

One of the most significant developments is the broader availability and FDA approval of CAR T-cell therapy for more lymphoma types. According to recent medical literature, anti-CD19 CAR T-cell therapy (which targets a specific protein on lymphoma cells) is now considered standard of care for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma after 2 or more lines of treatment.

What this means: If your lymphoma came back or didn't respond to initial treatment, you may now have access to this cellular therapy option—essentially using your own immune cells engineered to fight the cancer. Three FDA-approved CAR T products are now available for various lymphoma subtypes, including follicular lymphoma and mantle cell lymphoma.

2. Molecular Residual Disease (MRD) Testing

A newer tool called molecular residual disease (MRD) testing can now detect remaining cancer cells in your blood after treatment using circulating tumor DNA (ctDNA)—essentially looking for traces of cancer DNA. According to the NCCN Guidelines for B-Cell Lymphomas (updated December 2024), this test can identify molecular recurrence before symptoms appear, potentially leading to earlier intervention.

What this means: Your care team can now monitor you more precisely after treatment and may adjust follow-up plans based on whether any cancer cells remain detectable at the molecular level.

3. Better Biomarker Testing

According to the NCCN Guidelines for Patients with Marginal Zone Lymphomas, mutation testing has become more sophisticated. Your lymphoma cells can be tested for specific genetic changes that may respond to targeted therapies. These tests can identify new mutations that develop over time or during treatment, which helps guide therapy choices.

What Hasn't Changed Much

• Core treatment approaches (chemotherapy, immunotherapy with rituximab, radiation) remain foundational
• Staging and diagnostic imaging (CT scans, PET scans, bone marrow biopsies) are still standard
• The importance of your specific lymphoma subtype in determining treatment

Questions to Ask Your Oncologist

Since your diagnosis was during COVID, it's worth having an updated conversation with your care team:

1. "Have there been any new treatment options approved for my specific type of lymphoma since my diagnosis?"
2. "Am I a candidate for CAR T-cell therapy if my lymphoma returns or doesn't respond to current treatment?"
3. "Would molecular residual disease (MRD) testing be helpful in monitoring my response to treatment?"
4. "Are there any clinical trials available for my lymphoma subtype that I should know about?"
5. "How has my treatment plan evolved based on the latest guidelines?"

Where to Learn More

• NCCN Guidelines for Patients (nccn.org) - Specific guides for different lymphoma types
• National Cancer Institute (NCI) - Current information on lymphoma treatment
• Lymphoma Research Foundation (lymphoma.org) - Patient resources and support

The good news is that lymphoma treatment continues to improve, with more personalized options becoming available. Your oncologist can best explain which advances are most relevant to your specific situation and whether any new approaches might benefit you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.